Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Patent Grant: Genprex, Inc. has received a patent from the USPTO for its lead drug candidate, Reqorsa® Gene Therapy, in combination with PD-L1 antibodies, securing exclusivity for this treatment until 2037.

Acclaim-3 Clinical Trial: The Acclaim-3 trial is evaluating the combination of Reqorsa and Tecentriq® as maintenance therapy for patients with extensive stage small cell lung cancer, with a focus on progression-free survival rates.

Expansion and Enrollment: The Phase 2 expansion of the Acclaim-3 trial aims to enroll approximately 50 patients, with an interim analysis planned after the first 25 patients complete 18 weeks of follow-up.

Company Overview: Genprex is a clinical-stage gene therapy company developing therapies for cancer and diabetes, utilizing innovative delivery systems to administer disease-fighting genes.